Highlights: -More data needed for routine use of TAVI in lower risk patients -First randomised trial of Absorb indicates device has similar one-year clinical outcomes to Xience -Guillaume Cayla: DAPT duration -Leon Neething: Repairing hearts -Profile: Flavio Ribichini
[pdfviewer width=”100%” height=”940px” beta=”true”]http://cardiovascularnews.com/wp-content/uploads/sites/14/2016/06/CN36-low-res_USA.pdf[/pdfviewer]
